Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Platinum-refractory Ovarian Cancer
NCT00543049Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- Sep 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib in ovarian cancer (2 arms), sponsored by AGO Study Group. Primary endpoint: Objective Response Rate at 1 year. Started Sep 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00543049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543049.